The efficacy of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A meta-analysis and reconstructed individual patient data analysis.
Fuxun Zhang, Yang Xiong, Zhirong Luo et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis with reconstructed individual patient data assessed immune checkpoint inhibitors (ICIs) in men with metastatic castration-resistant prostate cancer (mCRPC), using data from 21 clinical trials involving 1,580 patients without biomarker-selected indications. Outcomes included overall survival (OS), radiographic progression-free survival (PFS), and objective response rate. Pooled OS was 63% at 1 year and 39% at 2 years; pooled PFS was 41% at 6 months and 17% at 12 months. ICI combined with another agent was associated with greater OS and PFS benefit than monotherapy or dual-ICI therapy.
Key findings
- Across 1,580 patients, pooled OS was 63% at 1 year and 39% at 2 years.
- Pooled PFS was 41% at 6 months and 17% at 12 months.
- ICI plus another agent showed greater OS and PFS benefit than mono- or dual-ICI therapy (all P < .05).
Why it matters
The pooled estimates describe outcomes with ICI in mCRPC populations not selected by biomarkers, while the comparison suggests that combining an ICI with another agent may warrant further evaluation. These findings help frame the current evidence but do not establish which combination is effective or suitable for routine use.
What to keep in mind
Individual patient data were reconstructed from published survival curves rather than obtained directly. The analysis pooled results from clinical trials with potentially differing regimens and populations.